@article {Aly:2017::e126,
title = "The study of a possible correlation between serum levels of interleukin 17 and clinical severity in patients with allergic rhinitis",
journal = "",
parent_itemid = "",
publishercode ="",
year = "2017",
volume = "8",
number = "3",
publication date ="2017-10-01T00:00:00",
pages = "e126-e131",
itemtype = "ARTICLE",
url = "https://www.ingentaconnect.com/content/ocean/rhino/2017/00000008/00000003/art00003",
doi = "doi:10.2500/ar.2017.8.0207",
keyword = "Allergic rhinitis, severity of allergy, correlation between IL-17 and severity, IgE, IL-17 relation to immunotherapy, interleukin 17, immunotherapy",
author = "Aly, Mai Aly Gharib and El Tabbakh, Mohamed Tawfik and Heissam, Waheed Fawzy and Abbadi, Said Hamed",
abstract = "
Introduction:
Allergic rhinitis (AR) is one of the most common allergic diseases, which affects 20% of the world's population. T-helper (Th) type 2 cells produce interleukin (IL) 4 and IL-13, and mediate allergic responses, and these cytokines have been extensively studied
as key players in the atopic airway diseases. However, the involvement of Th17 cells and IL-17 in AR has not been clearly examined. 
Aim:
To reevaluate AR clinical severity with serum IL-17, whether IL-17 affects the disease alone or in contribution with the atopic predisposition.
Patients and Methods:
During an 18-month period, 39 individuals were divided into three groups: A, (13 control), B (13 with mild-to-moderate AR), and C (13 with severe AR). Both group B and group C patients (26) were subjected to clinical examination and allergy skin testing,
and to measurement of both total serum immunoglobulin E (IgE) and IL-17 levels. Eleven patients with AR then were exposed to 6 months of cluster immunotherapy, whereas the rest of the patients were not exposed. 
Results:
Revealed a significant elevation of serum IL-17 levels
with an associated increase in serum IgE in the patients with AR compared with controls and revealed that the serum levels of both total serum IgE and IL-17 decreased significantly after cluster immunotherapy. 
Conclusion:
These preliminary results added new data about the
use of injective immunotherapy as well as reported on the use of sublingual immunotherapy.",
}